Coave Therapeutics Unveils Lead Gene Therapy Program, CoTx-10

Coave Therapeutics has announced the development of its lead gene therapy program, CoTx-10, intended for the treatment of retinal vascular diseases, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

A Dual-Targeted Approach to Retinal Disease

According to the company, CoTx-10 combines a best-in-class in-office delivery procedure with a first-in-class vector known as coAAV-SCS. This proprietary platform is designed to achieve deep retinal penetration, broad tissue coverage, and sustained expression of two biologics that target the angiogenesis pathway.

The in-office procedure is described as offering the highest potential clinical benefit while maintaining a low treatment burden for patients.

Coave Therapeutics reported plans to complete TPP-validating non-human primate studies of CoTx-10 by 2026, with the goal of being IND-ready in 2027.

Company Leadership Perspective

“The launch of our lead therapeutic suprachoroidal program validates our delivery-first approach to redefining targeted gene therapy,” said Rodolphe Clerval, CEO of Coave Therapeutics. “With our first-in-class ligand-conjugated AAVs, we are creating precision vectors that are highly tissue-specific, precisely delivered, and safer, powering targeted gene therapies. CoTx-10 aims to bring patients the ultimate treatment for retinal vascular diseases, offering the efficacy and safety of biologics with the unique durability of gene therapy.”

New Data Presented at ESGCT 2025

Coave Therapeutics also announced that it presented new data at the European Society of Gene and Cell Therapy (ESGCT) Congress 2025, where its novel vector demonstrated unprecedented transduction efficacy of RPE and photoreceptors in non-human primate studies.

The data also showed evasion from the immune system, supporting the potential for safer and more effective treatment, and suggesting the possibility of second-eye therapy for patients.